By John Carroll Seattle Genetics has turned in a promising new batch of data on its antibody/chemo combo for Hodgkin’s lymphoma and says it is now positioned to take a short cut to regulatory approval. The biotech’s drug, brentuximab vedotin, relies on an antibody to home in on a tumor and then drops its chemo …
By Maureen Martino Dealmaking machine Seattle Genetics is expecting a busy fall, says Seeking Alpha. Between September and October, the drug developer will recieve results from up to three clinical trials, two of which cover the company’s flagship drug SGN-35 (brentuximab vedotin). The drug, which has been fast-tracked by the FDA, is in Phase III testing for Hodgkin’s …
By John Carroll Genentech has anted up $12 million to expand its development pact for Seattle Genetics’ antibody-drug conjugate (ADC) technology. And the Seattle biotech will now be able to play for a pot of cash that could swell to $900 million in fees and milestones. Genentech has already shelled out $30 million to Seattle …
